An evaluation of sotalol, a β-blocking agent, in patients with angina pectoris

In a multi-centre study, sotalol was compared with placebo in 146 patients with angina pectoris using a double-blind crossover design. Sotalol had a significant effect in reducing the number of anginal attacks and the number of nitroglycerin tablets used. The medication was safe and produced minimal side effects.